Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection.

× No keyword cloud information.

12 in total

1. Ertapenem-induced reduction in valproate levels: case report and review of the literature.

Authors: Duane Bates; Michael Parkins; Keltie Duggan
Journal: Can J Hosp Pharm Date: 2010-07

2. In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli.

Authors: Teresa Spanu; Giulia De Angelis; Michela Cipriani; Barbara Pedruzzi; Tiziana D'Inzeo; Maria Adriana Cataldo; Gabriele Sganga; Evelina Tacconelli
Journal: Antimicrob Agents Chemother Date: 2012-05-29 Impact factor: 5.191

3. Tigecycline treatment of urinary tract infection and prostatitis: case report and literature review.

Authors: Duane Bates; Mike Parkins; Robin Hellweg; Kimberly Gibson; Jennifer M Bugar
Journal: Can J Hosp Pharm Date: 2012-05

4. Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis.

Authors: Burke A Cunha
Journal: J Clin Microbiol Date: 2009-05 Impact factor: 5.948

5. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine.

Authors: Michael J Satlin; Christine J Kubin; Jill S Blumenthal; Andrew B Cohen; E Yoko Furuya; Stephen J Wilson; Stephen G Jenkins; David P Calfee
Journal: Antimicrob Agents Chemother Date: 2011-10-03 Impact factor: 5.191

Review 10. Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities.

Authors: Muhammad Asif; Iqbal Ahmad Alvi; Shafiq Ur Rehman
Journal: Infect Drug Resist Date: 2018-08-21 Impact factor: 4.003

Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection.

1. Ertapenem-induced reduction in valproate levels: case report and review of the literature.

2. In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli.

3. Tigecycline treatment of urinary tract infection and prostatitis: case report and literature review.

4. Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis.

5. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine.

6. Current and novel antibiotics against resistant Gram-positive bacteria.

7. Once Daily High Dose Tigecycline Is Optimal: Tigecycline PK/PD Parameters Predict Clinical Effectiveness.

8. Infections Caused by Antimicrobial Drug-Resistant Saprophytic Gram-Negative Bacteria in the Environment.

9. Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients.

Review 10. Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities.